The early diagnosis of Connective Tissue Diseases has been one of the most important achievement in Rheumatology and imaging advanced thechnology has helped to reach this result.
The aim of the 9th intensive and interactive EULAR Course on Capillaroscopy (CAP) is to provide all participants with an update on the power of the safe and non-invasive nailfold videocapillaroscopy (NVC) technique in the field of rheumatic diseases, in particular for the early diagnosis of the scleroderma spectrum disorders, its predictability and prognostic value, as well as its role as a tool for the therapeutic follow up.
ACR/EULAR stated in the 2013 guidelines for classification criteria of systemic sclerosis (SSc): "Capillaroscopy is now widely used, and considering the value of magnified nailfold visualization in the diagnosis and management of SSc, these new criteria may encourage acquisition of this skill by physicians caring for SSc patients". However, microvascular emerging NVC patterns observed in other connective tissue diseases will be described and discussed, such as in psoriasis, psoriatic arthritis, antiphospholipid syndrome, systemic lupus eryjthematosus and myositis.
Therefore, the course is structured for a progressive learning, training and testing the achievements by the participants. The EULAR course on NVC, with more then 15 years of experience (first on 2004), has been successfully tested for both beginners and already trained operators in microcirculation investigations, by over 1010 total participants from almost 64 different countries.
Interesting, in the last 5 years, more than 425 publications on CAP become available on PubMed where a total of 1450 papers are reported from 1947.
Participants to the EULAR CAP Course will be fully involved in interactive theoretical and practical sessions (Learning and Testing sessions, including televoter at the beginning and at the end), engaging a large number of rheumatic patients with different pathologies.
Updated clinical sessions concerning the diagnostic/prognostic value of NVC in diseases such as systemic sclerosis and the effects of targeted therapies on microcirculation and immune-inflammatory reaction will represent a stimulating gym based on large clinical cases discussion. Links between the CAP patterns and biomarkers such as autoantibodies (including functional) will also be updated.
In particular, reading and scoring (manual and the brand new automated systems) of the videocapillaroscopic images of living patients, will be discussed, including the predictive value to identify possible clinical complications (i.e. digital ulcers or pulmonary arterial hypertension, etc.).
The new guidelines and results regarding the aspects of CAP in pediatric population will be reported.
Further sessions will include recent international studies (CAP study) about new predictive models or index based on capillaroscopic analysis.
New sessions on practical evaluation of the peripheral blood flow by laser doppler and LASCA imaging have been introduced. In addition, practical sessions on skin ultrasound (US) evaluation in scleroderma will be also available and will be combined with the severity of the videocapillaroscopic images (patterns) in the same living patients.
Several monitors will show on live TV shots of the practical sessions with patients. Interactive sessions with evaluation of the learning status will be organised at the end of each session. Important links between CAP, Laser blood flow analysis and clinical results of therapies, will be presented and discussed.
At the end of this top Course, that is supported by a tutorial team formed by some of the best world experts on the matter, the participants will be able to use the capillaroscopy for their day-to-day diagnosis, staging and follow-up, in particular of patients affected by scleroderma spectrum disorders.
A syllabus of the Course with selected slides will be released to all participants on USB format.
Updating on the power of the safe (the most safe) and non-invasive nailfold videocapillaroscopy (NVC) technique in the field of rheumatic diseases, in particular for the (early) diagnosis of the scleroderma spectrum disorders and several other connective tissue diseases, as well as its predictability and prognostic value and tool for the therapeutic follow up in systemic sclerosis.